Sorrento Acquires Four Biosimilar Candidates
Sorrento Therapeutics, a clinical-stage oncology company, has entered into an exclusive licensing agreement to develop and commercialize four undisclosed late-stage biosimilar candidates from Mabtech Limited, a holding company for antibody development and manufacturing companies in China.
Under the agreement, Sorrento will acquire the rights to develop and market these monoclonal antibodies (mAbs) for the North American, European, and Japanese markets. Each of the four mAbs has completed a Phase III study. Two are currently in registration for marketing approval in China, and the other two are under data analyses for subsequent new drug application submission in China.
Source: Sorrento Therapeutics